Daiichi sends in posse to keep Ranbaxy plant in line

Daiichi Sankyo isn't taking chances on Ranbaxy Laboratories' ability to keep turning out FDA-compliant drugs. The Japanese drugmaker, which owns the controlling interest in the Indian company, has dispatched two executives to the Punjab facility to keep a close eye on operations there, The Economic Times says. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.